Amundi Has $500.89 Million Stock Holdings in Cencora, Inc. $COR

Amundi boosted its position in Cencora, Inc. (NYSE:COR) by 17.0% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 1,720,278 shares of the company’s stock after purchasing an additional 249,742 shares during the period. Amundi owned about 0.89% of Cencora worth $500,893,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Intrust Bank NA acquired a new stake in shares of Cencora in the first quarter valued at approximately $225,000. Goldman Sachs Group Inc. lifted its holdings in Cencora by 9.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company’s stock valued at $475,890,000 after purchasing an additional 154,311 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Cencora by 1.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,045,819 shares of the company’s stock valued at $290,832,000 after purchasing an additional 17,948 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Cencora by 10.3% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,077 shares of the company’s stock worth $85,395,000 after purchasing an additional 28,791 shares during the period. Finally, AlphaCore Capital LLC increased its holdings in shares of Cencora by 15.7% in the first quarter. AlphaCore Capital LLC now owns 1,845 shares of the company’s stock valued at $513,000 after purchasing an additional 251 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 46,640 shares of company stock worth $14,099,338 over the last three months. 10.80% of the stock is currently owned by insiders.

Cencora Stock Performance

COR opened at $339.28 on Friday. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. Cencora, Inc. has a 52-week low of $223.92 and a 52-week high of $377.54. The firm has a market cap of $65.82 billion, a P/E ratio of 42.68, a price-to-earnings-growth ratio of 1.60 and a beta of 0.63. The business’s fifty day moving average is $340.04 and its 200-day moving average is $309.49.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. Cencora’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were given a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is 30.19%.

Analyst Upgrades and Downgrades

COR has been the subject of a number of research reports. JPMorgan Chase & Co. raised their target price on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Robert W. Baird increased their target price on Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, TD Cowen boosted their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $371.09.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.